logo
Share SHARE
FONT-SIZE Plus   Neg

Vertex Reports Interim Analysis Data From Phase 2 Study Of VX-809 And Kalydeco

Vertex Pharmaceuticals Inc. (VRTX) announced an interim analysis of data from an ongoing Phase 2 study of VX-809 and Kalydeco (ivacaftor) that showed significant improvements in lung function or FEV1 among adults with cystic fibrosis or CF who have two copies (homozygous) of the most common mutation in the cystic fibrosis transmembrane conductance regulator or CFTR gene, F508del.

A planned interim analysis was conducted after approximately half of the study patients had completed 56 days of treatment.

The company said that today's results are based on data from 37 homozygous F508del patients who completed treatment in the 56-day study and 11 patients with one or two copies of the F508del mutation who received placebo.

According to interim analysis of data, there was a statistically significant improvement in lung function (absolute change in percent predicted FEV1) across the combined treatment groups relative to baseline compared to placebo (p=0.002). Of those who received VX-809 and Kalydeco (250mg, q12h), approximately 46 percent (17/37) experienced an absolute improvement from baseline to Day 56 in lung function of 5 percentage points or more, and approximately 30 percent (11/37) experienced an absolute improvement from baseline to Day 56 of 10 percentage points or more.

The company stated that none of the patients treated with placebo (0/11) achieved a 5-percentage point or more improvement from baseline to Day 56 in lung function. Most adverse events were mild or moderate in severity and comparable between treatment and placebo groups.

The study is ongoing and complete data, including statistical analyses for all patient groups, will be available in mid-2012.

Vertex noted that it plans to start a pivotal study of VX-809 and Kalydeco in people with two copies of the F508del mutation, pending final study results and discussions with regulatory agencies.

by RTT Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Quick Facts

Editors Pick
A new Nike ad, "Unlimited Pursuit," highlights the hard work and dedication of female Olympians it takes to be the best. The latest installment in the Nike "Unlimited" - Just Do It campaign features some of world's greatest athletes from Rio 2016 Olympics. Gymnasts Simone Biles and Gabby Douglas, tennis player Serena Williams and many others are shown in the 40-second clip. Amazon.com on Wednesday announced the launch of Kindle Reading Fund, aiming to donate Kindle e-reader, Fire tablets, and Kindle eBooks globally to make books more easily available for digital reading. For this purpose, the company joining hands with local schools and libraries, hospitals, PTA as well as nonprofit organizations, mainly Worldreader. A federal judge has dismissed a lawsuit that accused Starbucks (SBUX) of cheating customers by "under-filling" its cold beverages. The lawsuit alleged that Starbucks is deceiving its customers by serving iced drinks with too much ice cubes and less coffee "than advertised." "If children have figured...
comments powered by Disqus
Follow RTT